EUVIMEDEUVIMED entdecken
Crossref

Associations of TILs and genomic alterations in HER2+ early breast cancer

Shuangshuang Lu iD, Jiahui Huang, Yijin Gu, Chaofu Wang, Kunwei Shen, Xiaochun Fei, Xiaosong Chen

Endocrine-Related Cancer · 01.08.2026 · 33 (8)

DOI: 10.1530/erc-25-0411 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, online erschienen am 05.08.2026. Verfasst von Shuangshuang Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Lymphocytes, Tumor-Infiltrating. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigated the associations between tumor-infiltrating lymphocytes (TILs), genomic features, and prognosis in HER2+ early breast cancer (EBC) patients receiving adjuvant trastuzumab. We retrospectively analyzed 864 HER2+ EBC patients from Shanghai Ruijin Hospital (2009–2017). The optimal threshold of TILs for predicting disease-free survival (DFS) and overall survival (OS) was explored. Whole-exome sequencing (WES) on 261 tumors assessed the mutational profiles, tumor mutational burden (TMB), and copy number alteration (CNA). Associations between these genomic features, TIL levels, and prognosis were further evaluated. TILs showed a right-skewed distribution (median: 15%, IQR: 1–30%), and higher TIL levels were significantly associated with hormone receptor negativity and high histologic grade (P < 0.001). A 15% TIL threshold optimally predicted prognosis, with low-TIL (≤15%, 63.0%) patients showing inferior DFS (HR: 1.63, P = 0.009) and OS (HR: 2.12, P = 0.037). WES identified frequent mutations in TP53 (62.8%), PIK3CA (34.5%), and BRCA2 (9.6%). A higher TIL density was observed in TP53-wild-type, low-TMB or low-CNA tumors (P < 0.05). PIK3CA mutations conferred a significant DFS advantage. Integrating TIL level with PIK3CA or BRCA2 mutational status yielded distinct DFS trajectories (log-rank P = 0.023 and 0.040, respectively); patients with both high TIL levels and either PIK3CA or BRCA2 mutations had the most favorable outcomes. Stromal TILs at a 15% cutoff provide robust prognostic information in trastuzumab-treated HER2+ EBC. Integrating TIL levels with PIK3CA or BRCA2 mutational status enables refined risk stratification, offering a practical framework for personalized treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsLymphocytes, Tumor-InfiltratingHumansFemaleErb-b2 Receptor Tyrosine KinasesMiddle AgedPrognosisRetrospective StudiesMutationAdultTrastuzumabAged

Stichwörter der Autor:innen

breast neoplasmsexome sequencingprognostic factorsretrospective studiestrastuzumabtumor-infiltrating lymphocytes

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanTrastuzumab

Autor:innen und Institutionen

  • Department of General Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai, China.
  • Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai, China.
  • Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai, China.

ORCID-Profile: Shuangshuang Lu

Zitieren

APA

Lu, S., Huang, J., Gu, Y., Wang, C., Shen, K., Fei, X., & Chen, X. (2026). Associations of TILs and genomic alterations in HER2+ early breast cancer. Endocrine-Related Cancer, 33(8). https://doi.org/10.1530/erc-25-0411

Vancouver

Lu S, Huang J, Gu Y, Wang C, Shen K, Fei X, et al. Associations of TILs and genomic alterations in HER2+ early breast cancer. Endocrine-Related Cancer. 2026;33(8). doi:10.1530/erc-25-0411

BibTeX
@article{Lu2026,
  author = {Lu, Shuangshuang and Huang, Jiahui and Gu, Yijin and Wang, Chaofu and Shen, Kunwei and Fei, Xiaochun and Chen, Xiaosong},
  title = {Associations of TILs and genomic alterations in HER2+ early breast cancer},
  journal = {Endocrine-Related Cancer},
  year = {2026},
  volume = {33},
  number = {8},
  doi = {10.1530/erc-25-0411}
}
Kostenlos starten →